The resistance to chemotherapeutic drugs by
cancer cells is considered to be one of the major obstacles for success in the treatment of
cancer. A major mechanism underlying this multidrug resistance is the overexpression of
P-glycoprotein (P-gp), resulting in insufficient
drug delivery to the
tumor sites. A previous study has shown that
stemofoline, an
alkaloid isolated from Stemona burkillii, could enhance the sensitivity of chemotherapeutics in a synergistic fashion. In the present study, we have focused on the effect of
stemofoline on the modulation of P-gp function in a multidrug resistant human cervical
carcinoma cell line (KB-V1). The effects of
stemofoline on a radiolabeled
drug, [(3)H]-
vinblastine, and fluorescent P-gp substrates,
rhodamine 123 and
calcein-AM accumulation or retention were investigated to confirm this finding.
Stemofoline could increase the accumulation or retention of radiolabeled drugs or fluorescent P-gp substrates in a dose-dependent manner. For additional studies on
drug-P-gp binding, P-gp
ATPase activity was stimulated by
stemofoline in a concentration-dependent manner. More evidence was offered that
stemofoline inhibits the effect on photoaffinity labeling of P-gp with [(125)I]-iodoarylazidoprazosin in a concentration-dependent manner. These data indicate that
stemofoline may interact directly with P-gp and inhibit P-gp activity, whereas
stemofoline has no effect on P-gp expression. Taken together, the results exhibit that
stemofoline possesses an effective MDR modulator, and may be used in combination with conventional chemotherapeutic drugs to reverse MDR in
cancer cells.